The Fate of Pancuronium Bromide in Man

The fate of pancuronium bromide has been investigated in 20 anaesthetized patients, seven undergoing cholecystectomy with choledochostomy (Group I), seven undergoing cholecystectomy only (Group II) and six undergoing pelvic operations (Group III). A fluorimetric method was used to determine pancuronium bromide and its bis‐quaternary derivatives in blood, urine and bile. After a single intravenous injection of 6 mg pancuronium bromide, disappearance of the drug from the plasma proceeded in three phases with half‐lives of < 5 min, 7‐13 min and 108–147 min, respectively. Renal elimination is suggested as the major excretory pathway in man, but biliary excretion is also significant. Thirty hours after injection, the total recovery of unchanged pancuronium and its metabolite was approximately 37–44% in the urine (Groups I, II, III) and 11% in the bile (Group I). Only one metabolite (3‐hydroxy derivative) of pancuronium bromide, accounting in total for about 15% of the administered dose, was identified in urine and 5% in bile by thin‐layer chromatography. Renal and hepatic elimination varied widely between patients.

[1]  D. Meijer,et al.  The Fate of Pancuronium Bromide in the Cat , 1973, Acta anaesthesiologica Scandinavica.

[2]  D. Meijer,et al.  Fluorimetric and chromatographic determination of pancuronium bromide and its metabolites in biological materials. , 1973, Clinica chimica acta; international journal of clinical chemistry.

[3]  M. Gibaldi,et al.  Kinetics of the Elimination and Neuromuscular Blocking Effect of d-Tubocurarine in Man , 1972, Anesthesiology.

[4]  M. Gibaldi,et al.  Tubocurarine and renal failure. , 1972, British journal of anaesthesia.

[5]  W. Maisel,et al.  Studies of Pancuronium in Conscious and Anesthetized Man , 1971, Anesthesiology.

[6]  L. Theodorsen,et al.  Sensitivity to gallamine and pancuronium with special reference to serum proteins. , 1971, British journal of anaesthesia.

[7]  A. Dobkin,et al.  Pancuronium bromide (Pavulon®) evaluation of its clinical pharmacology , 1971, Canadian Anaesthetists' Society journal.

[8]  J. McIntyre,et al.  Initial experience during the clinical use of pancuronium bromide. , 1971, Anesthesia and Analgesia.

[9]  R. Katz Clinical Neuromuscular Pharmacology of Pancuronium , 1971, Anesthesiology.

[10]  K. Bihler,et al.  [Determination of pancuronium bromide in the urine]. , 1971, Der Anaesthesist.

[11]  J. Norman,et al.  The neuromuscular blocking action of pancuronium in man during anaesthesia. , 1972, British journal of anaesthesia.

[12]  S. Feldman,et al.  Interaction of Diazepam with the Muscle-relaxant Drugs , 1970, British medical journal.

[13]  D. Meijer,et al.  Curare-like agents: relation between lipid solubility and transport into bile in perfused rat liver. , 1970, European journal of pharmacology.

[14]  A. M. Reid,et al.  The neuromuscular blocking properties of a new steroid compound, pancuronium bromide. A pilot study in man. , 1967, British journal of anaesthesia.

[15]  E. N. Cohen,et al.  STUDIES OF d‐TUBOCURARINE WITH MEASUREMENTS OF CONCENTRATION IN HUMAN BLOOD , 1957, Anesthesiology.

[16]  W. Kalow Urinary excretion of d-tubocurarine in man. , 1953, The Journal of pharmacology and experimental therapeutics.